documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
199 rows where docket_id = "FDA-2007-D-0369" and posted_year = 2023 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, comment_end_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 3
- Other 156
- Supporting & Related Material 36
- Notice 7
posted_year 1
- 2023 · 199 ✖
agency_id 1
- FDA 199
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2007-D-0369-0949 | FDA | None FDA-2007-D-0369 | PSG_214962 - Draft Guidance on Fingolimod Lauryl Sulfate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:46Z | 1 | 0 | 0900006486286f24 | |
| FDA-2007-D-0369-0953 | FDA | None FDA-2007-D-0369 | PSG_214120 - Draft Guidance on Azacitidine | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:47Z | 1 | 0 | 0900006486286f2d | |
| FDA-2007-D-0369-0955 | FDA | None FDA-2007-D-0369 | PSG_214958 - Draft Guidance on Deucravacitinib | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:47Z | 1 | 0 | 0900006486286f31 | |
| FDA-2007-D-0369-0967 | FDA | None FDA-2007-D-0369 | PSG_215446 - Draft Guidance on Edaravone | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:49Z | 1 | 0 | 0900006486286f4a | |
| FDA-2007-D-0369-0933 | FDA | None FDA-2007-D-0369 | PSG_021254 - Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:44Z | 1 | 0 | 0900006486286f00 | |
| FDA-2007-D-0369-0938 | FDA | None FDA-2007-D-0369 | PSG_021433 - Draft Guidance on Fluticasone Propionate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:44Z | 1 | 0 | 0900006486286f0a | |
| FDA-2007-D-0369-0937 | FDA | None FDA-2007-D-0369 | PSG_014602 - Draft Guidance on Betamethasone Acetate; Betamethasone Sodium Phosphate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:44Z | 1 | 0 | 0900006486286f08 | |
| FDA-2007-D-0369-0945 | FDA | None FDA-2007-D-0369 | PSG_205641 - Draft Guidance on Mometasone Furoate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:46Z | 1 | 0 | 0900006486286f18 | |
| FDA-2007-D-0369-0930 | FDA | None FDA-2007-D-0369 | PSG_017643 - Draft Guidance on Soybean Oil | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:43Z | 1 | 0 | 0900006486287259 | |
| FDA-2007-D-0369-0942 | FDA | None FDA-2007-D-0369 | PSG_206317 - Draft Guidance on Ferric Pyrophosphate Citrate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:45Z | 1 | 0 | 0900006486286f12 | |
| FDA-2007-D-0369-0960 | FDA | None FDA-2007-D-0369 | PSG_215256 - Draft Guidance on Semaglutide | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:48Z | 1 | 0 | 0900006486286f3c | |
| FDA-2007-D-0369-0948 | FDA | None FDA-2007-D-0369 | PSG_209637 - Draft Guidance on Semaglutide | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-12-14T02:00:54Z | 1 | 0 | 0900006486286f22 | |
| FDA-2007-D-0369-0959 | FDA | None FDA-2007-D-0369 | PSG_215092 - Draft Guidance on Omidenepag Isopropyl | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:48Z | 1 | 0 | 0900006486286f3a | |
| FDA-2007-D-0369-0962 | FDA | None FDA-2007-D-0369 | PSG_216903 - Draft Guidance on Glycopyrrolate; Neostigmine Methylsulfate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:49Z | 1 | 0 | 0900006486286f40 | |
| FDA-2007-D-0369-0928 | FDA | None FDA-2007-D-0369 | PSG_021395 - Draft Guidance on Tiotropium Bromide | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:43Z | 1 | 0 | 0900006486287255 | |
| FDA-2007-D-0369-0929 | FDA | None FDA-2007-D-0369 | PSG_020503 - Draft Guidance on Albuterol Sulfate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:43Z | 1 | 0 | 0900006486287257 | |
| FDA-2007-D-0369-0944 | FDA | None FDA-2007-D-0369 | PSG_022544 - Draft Guidance on Gabapentin | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:45Z | 1 | 0 | 0900006486286f16 | |
| FDA-2007-D-0369-0954 | FDA | None FDA-2007-D-0369 | PSG_209988 - Draft Guidance on Furosemide | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:47Z | 1 | 0 | 0900006486286f2f | |
| FDA-2007-D-0369-0935 | FDA | None FDA-2007-D-0369 | PSG_017768 - Draft Guidance on Chlorhexidine Gluconate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:44Z | 1 | 0 | 0900006486286f04 | |
| FDA-2007-D-0369-0964 | FDA | None FDA-2007-D-0369 | PSG_215401 - Draft Guidance on Dextroamphetamine | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:49Z | 1 | 0 | 0900006486286f44 | |
| FDA-2007-D-0369-0966 | FDA | None FDA-2007-D-0369 | PSG_216354 - Draft Guidance on Deutetrabenazine | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:49Z | 1 | 0 | 0900006486286f48 | |
| FDA-2007-D-0369-0958 | FDA | None FDA-2007-D-0369 | PSG_215272 - Draft Guidance on Tapinarof | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:48Z | 1 | 0 | 0900006486286f38 | |
| FDA-2007-D-0369-0927 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-05-16T20:18:05Z | 2023-25485 | 0 | 0 | 090000648628cbd3 |
| FDA-2007-D-0369-0934 | FDA | None FDA-2007-D-0369 | PSG_021344 - Draft Guidance on Fulvestrant | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2023-11-17T20:16:37Z | 0 | 0 | 0900006486286f02 | |
| FDA-2007-D-0369-0939 | FDA | None FDA-2007-D-0369 | PSG_208551 - Draft Guidance on Ferric Pyrophosphate Citrate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:45Z | 1 | 0 | 0900006486286f0c | |
| FDA-2007-D-0369-0947 | FDA | None FDA-2007-D-0369 | PSG_022180 - Draft Guidance on Ferumoxytol | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:46Z | 1 | 0 | 0900006486286f20 | |
| FDA-2007-D-0369-0957 | FDA | None FDA-2007-D-0369 | PSG_214665 - Draft Guidance on Sotorasib | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:48Z | 1 | 0 | 0900006486286f36 | |
| FDA-2007-D-0369-0931 | FDA | None FDA-2007-D-0369 | PSG_009170 - Draft Guidance on Primidone | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:43Z | 1 | 0 | 0900006486286efc | |
| FDA-2007-D-0369-0946 | FDA | None FDA-2007-D-0369 | PSG_021897 - Draft Guidance on Naltrexone | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:46Z | 1 | 0 | 0900006486286f1e | |
| FDA-2007-D-0369-0950 | FDA | None FDA-2007-D-0369 | PSG_209354 - Draft Guidance on Halobetasol Propionate; Tazarotene | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:46Z | 1 | 0 | 0900006486286f26 | |
| FDA-2007-D-0369-0956 | FDA | None FDA-2007-D-0369 | PSG_212860 - Draft Guidance on Ferric Pyrophosphate Citrate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:47Z | 1 | 0 | 0900006486286f34 | |
| FDA-2007-D-0369-0963 | FDA | None FDA-2007-D-0369 | PSG_215904 - Draft Guidance on Ganaxolone | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:49Z | 1 | 0 | 0900006486286f42 | |
| FDA-2007-D-0369-0932 | FDA | None FDA-2007-D-0369 | PSG_020622 - Draft Guidance on Glatiramer Acetate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:43Z | 1 | 0 | 0900006486286efe | |
| FDA-2007-D-0369-0941 | FDA | None FDA-2007-D-0369 | PSG_208215 - Draft Guidance on Emtricitabine; Tenofovir Alafenamide Fumarate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:45Z | 1 | 0 | 0900006486286f10 | |
| FDA-2007-D-0369-0943 | FDA | None FDA-2007-D-0369 | PSG_021730 - Draft Guidance on Levalbuterol Tartrate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:45Z | 1 | 0 | 0900006486286f14 | |
| FDA-2007-D-0369-0951 | FDA | None FDA-2007-D-0369 | PSG_210655 - Draft Guidance on Risperidone | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:47Z | 1 | 0 | 0900006486286f29 | |
| FDA-2007-D-0369-0936 | FDA | None FDA-2007-D-0369 | PSG_017920 - Draft Guidance on Cimetidine | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:44Z | 1 | 0 | 0900006486286f06 | |
| FDA-2007-D-0369-0940 | FDA | None FDA-2007-D-0369 | PSG_021929 - Draft Guidance on Budesonide; Formoterol Fumarate Dihydrate | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:45Z | 1 | 0 | 0900006486286f0e | |
| FDA-2007-D-0369-0952 | FDA | None FDA-2007-D-0369 | PSG_214801 - Draft Guidance on Futibatinib | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:47Z | 1 | 0 | 0900006486286f2b | |
| FDA-2007-D-0369-0961 | FDA | None FDA-2007-D-0369 | PSG_216472 - Draft Guidance on Latanoprost | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:48Z | 1 | 0 | 0900006486286f3e | |
| FDA-2007-D-0369-0965 | FDA | None FDA-2007-D-0369 | PSG_215428 - Draft Guidance on Citalopram Hydrobromide | Other | Guidance | 2023-11-17T05:00:00Z | 2023 | 11 | 2023-11-17T05:00:00Z | 2024-01-17T04:59:59Z | 2024-11-12T06:22:49Z | 1 | 0 | 0900006486286f46 | |
| FDA-2007-D-0369-0887 | FDA | None FDA-2007-D-0369 | PSG_021258 Draft Guidance on Estradiol; Levonorgestrel | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:05Z | 1 | 0 | 0900006485ed5b4e | |
| FDA-2007-D-0369-0891 | FDA | None FDA-2007-D-0369 | PSG_201739 Draft Guidance on Epinephrine | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-08-23T03:59:59Z | 2024-11-11T21:31:06Z | 1 | 0 | 0900006485ed5b5c | |
| FDA-2007-D-0369-0921 | FDA | None FDA-2007-D-0369 | PSG_216359 Draft Guidance on Midazolam Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:08Z | 1 | 0 | 0900006485ed6325 | |
| FDA-2007-D-0369-0902 | FDA | None FDA-2007-D-0369 | PSG_020746 Draft Guidance on Budesonide | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:05Z | 1 | 0 | 0900006485ed5b46 | |
| FDA-2007-D-0369-0888 | FDA | None FDA-2007-D-0369 | PSG_021527 Draft Guidance on Ipratropium Bromide | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:06Z | 1 | 0 | 0900006485ed5b50 | |
| FDA-2007-D-0369-0916 | FDA | None FDA-2007-D-0369 | PSG_216227 Draft Guidance on Chloroprocaine Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2024-11-11T21:31:07Z | 1 | 0 | 0900006485ed6319 | ||
| FDA-2007-D-0369-0900 | FDA | None FDA-2007-D-0369 | PSG_008816 Draft Guidance on Lidocaine Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:04Z | 1 | 0 | 0900006485ed5b42 | |
| FDA-2007-D-0369-0915 | FDA | None FDA-2007-D-0369 | PSG_215833 Draft Guidance on Lutetium Lu-177 Vipivotide Tetraxetan | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:07Z | 1 | 0 | 0900006485ed627c | |
| FDA-2007-D-0369-0901 | FDA | None FDA-2007-D-0369 | PSG_020468 Draft Guidance on Triamcinolone Acetonide | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:05Z | 1 | 0 | 0900006485ed5b44 | |
| FDA-2007-D-0369-0896 | FDA | None FDA-2007-D-0369 | PSG_213433 Draft Guidance on Clascoterone | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:13Z | 1 | 0 | 0900006485ed5c47 | |
| FDA-2007-D-0369-0905 | FDA | None FDA-2007-D-0369 | PSG_214487 Draft Guidance on Avacopan | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:37Z | 1 | 0 | 0900006485ed5c59 | |
| FDA-2007-D-0369-0914 | FDA | None FDA-2007-D-0369 | PSG_214662 Draft Guidance on Maralixibat Chloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:40Z | 1 | 0 | 0900006485ed5c77 | |
| FDA-2007-D-0369-0920 | FDA | None FDA-2007-D-0369 | PSG_215866 Draft Guidance on Tirzepatide | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2025-02-23T05:15:13Z | 1 | 0 | 0900006485ed6321 | |
| FDA-2007-D-0369-0907 | FDA | None FDA-2007-D-0369 | PSG_214103 Draft Guidance on Lumasiran Sodium | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:38Z | 1 | 0 | 0900006485ed5c5d | |
| FDA-2007-D-0369-0911 | FDA | None FDA-2007-D-0369 | PSG_214998 Draft Guidance on Mavacamten | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:38Z | 1 | 0 | 0900006485ed5c71 | |
| FDA-2007-D-0369-0904 | FDA | None FDA-2007-D-0369 | PSG_214028 Draft Guidance on Pilocarpine Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:37Z | 1 | 0 | 0900006485ed5c4d | |
| FDA-2007-D-0369-0890 | FDA | None FDA-2007-D-0369 | PSG_022004 Draft Guidance on Ciclesonide | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:06Z | 1 | 0 | 0900006485ed5b5a | |
| FDA-2007-D-0369-0892 | FDA | None FDA-2007-D-0369 | PSG_205920 Draft Guidance on Epinephrine | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:06Z | 1 | 0 | 0900006485ed5b5e | |
| FDA-2007-D-0369-0917 | FDA | None FDA-2007-D-0369 | PSG_215888 Draft Guidance on Oteseconazole | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:07Z | 1 | 0 | 0900006485ed631b | |
| FDA-2007-D-0369-0919 | FDA | None FDA-2007-D-0369 | PSG_216196 Draft Guidance on Mitapivat Sulfate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2024-11-11T21:31:08Z | 1 | 0 | 0900006485ed631f | ||
| FDA-2007-D-0369-0885 | FDA | None FDA-2007-D-0369 | PSG_020911 Draft Guidance on Beclomethasone Dipropionate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:05Z | 1 | 0 | 0900006485ed5b4a | |
| FDA-2007-D-0369-0903 | FDA | None FDA-2007-D-0369 | PSG_021234 Draft Guidance on Diclofenac Epolamine | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:05Z | 1 | 0 | 0900006485ed5b48 | |
| FDA-2007-D-0369-0893 | FDA | None FDA-2007-D-0369 | PSG_208712 Draft Guidance on Pacritinib Citrate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:12Z | 1 | 0 | 0900006485ed5c34 | |
| FDA-2007-D-0369-0897 | FDA | None FDA-2007-D-0369 | PSG_213137 Draft Guidance on Voxelotor | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:13Z | 1 | 0 | 0900006485ed5c49 | |
| FDA-2007-D-0369-0906 | FDA | None FDA-2007-D-0369 | PSG_213581 Draft Guidance on Atropine Sulfate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-08-23T03:59:59Z | 2024-11-07T01:23:37Z | 1 | 0 | 0900006485ed5c5b | |
| FDA-2007-D-0369-0884 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-08-22T13:37:43Z | 2023-18026 | 0 | 0 | 0900006485ed5264 | |
| FDA-2007-D-0369-0886 | FDA | None FDA-2007-D-0369 | PSG_021658 Draft Guidance on Ciclesonide | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:05Z | 1 | 0 | 0900006485ed5b4c | |
| FDA-2007-D-0369-0918 | FDA | None FDA-2007-D-0369 | PSG_215358 Draft Guidance on Asciminib Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:08Z | 1 | 0 | 0900006485ed631d | |
| FDA-2007-D-0369-0898 | FDA | None FDA-2007-D-0369 | PSG_212097 Draft Guidance on Glucagon | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:40Z | 1 | 0 | 0900006485ed5c4b | |
| FDA-2007-D-0369-0909 | FDA | None FDA-2007-D-0369 | PSG_214985 Draft Guidance on Daridorexant Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:38Z | 1 | 0 | 0900006485ed5c61 | |
| FDA-2007-D-0369-0895 | FDA | None FDA-2007-D-0369 | PSG_211746 Draft Guidance on Mometasone Furoate; Olopatadine Hydrochloride | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:13Z | 1 | 0 | 0900006485ed5c45 | |
| FDA-2007-D-0369-0908 | FDA | None FDA-2007-D-0369 | PSG_213871 Draft Guidance on Abrocitinib | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:38Z | 1 | 0 | 0900006485ed5c5f | |
| FDA-2007-D-0369-0912 | FDA | None FDA-2007-D-0369 | PSG_215310 Draft Guidance on Mobocertinib Succinate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-08-23T03:59:59Z | 2024-11-07T01:23:38Z | 1 | 0 | 0900006485ed5c73 | |
| FDA-2007-D-0369-0899 | FDA | None FDA-2007-D-0369 | PSG_019389 Draft Guidance on Beclomethasone Dipropionate Monohydrate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:04Z | 1 | 0 | 0900006485ed5b27 | |
| FDA-2007-D-0369-0889 | FDA | None FDA-2007-D-0369 | PSG_022033 Draft Guidance on Fluvoxamine Maleate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:06Z | 1 | 0 | 0900006485ed5b58 | |
| FDA-2007-D-0369-0922 | FDA | None FDA-2007-D-0369 | PSG_215515 Draft Guidance on Vutrisiran Sodium | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-11T21:31:08Z | 1 | 0 | 0900006485ed6327 | |
| FDA-2007-D-0369-0910 | FDA | None FDA-2007-D-0369 | PSG_215206 Draft Guidance on Atogepant | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:38Z | 1 | 0 | 0900006485ed5c6f | |
| FDA-2007-D-0369-0894 | FDA | None FDA-2007-D-0369 | PSG_207921 Draft Guidance on Beclomethasone Dipropionate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:12Z | 1 | 0 | 0900006485ed5c36 | |
| FDA-2007-D-0369-0913 | FDA | None FDA-2007-D-0369 | PSG_215309 Draft Guidance on Ruxolitinib Phosphate | Other | Guidance | 2023-08-22T04:00:00Z | 2023 | 8 | 2023-08-22T04:00:00Z | 2023-10-24T03:59:59Z | 2024-11-07T01:23:40Z | 1 | 0 | 0900006485ed5c75 | |
| FDA-2007-D-0369-0867 | FDA | None FDA-2007-D-0369 | PSG_214793 - Draft Guidance on Piflufolastat F-18 | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:12Z | 1 | 0 | 0900006485a20d0a | |
| FDA-2007-D-0369-0868 | FDA | None FDA-2007-D-0369 | PSG_214916 - Draft Guidance on Difelikefalin Acetate | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-18T03:59:59Z | 2024-11-07T01:34:15Z | 1 | 0 | 0900006485a20c85 | |
| FDA-2007-D-0369-0860 | FDA | None FDA-2007-D-0369 | PSG_213691- Draft Guidance on Clobetasol Propionate | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:19Z | 1 | 0 | 0900006485a204e2 | |
| FDA-2007-D-0369-0866 | FDA | None FDA-2007-D-0369 | PSG_214783 - Draft Guidance on Belumosudil Mesylate | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:14Z | 1 | 0 | 0900006485a20c81 | |
| FDA-2007-D-0369-0871 | FDA | None FDA-2007-D-0369 | PSG_215457 - Draft Guidance on Naloxone Hydrochloride | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:13Z | 1 | 0 | 0900006485a20c89 | |
| FDA-2007-D-0369-0874 | FDA | None FDA-2007-D-0369 | PSG_018152 - Draft Guidance on Lithium Carbonate | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:18Z | 1 | 0 | 0900006485a23167 | |
| FDA-2007-D-0369-0857 | FDA | None FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-05-19T15:39:54Z | 2023-10710 | 0 | 0 | 0900006485a22a81 | |
| FDA-2007-D-0369-0865 | FDA | None FDA-2007-D-0369 | PSG_214461 - Draft Guidance on Brincidofovir | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:14Z | 1 | 0 | 0900006485a2057a | |
| FDA-2007-D-0369-0863 | FDA | None FDA-2007-D-0369 | PSG_214410 - Draft Guidance on Baloxavir Marboxil | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:11Z | 1 | 0 | 0900006485a20577 | |
| FDA-2007-D-0369-0875 | FDA | None FDA-2007-D-0369 | PSG_018558 - Draft Guidance on Lithium Carbonate | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:18Z | 1 | 0 | 0900006485a23169 | |
| FDA-2007-D-0369-0858 | FDA | None FDA-2007-D-0369 | PSG_213312 Draft Guidance on Sirolimus | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:10Z | 1 | 0 | 0900006485a1e362 | |
| FDA-2007-D-0369-0861 | FDA | None FDA-2007-D-0369 | PSG_213026 - Draft Guidance on Casimersen | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:14Z | 1 | 0 | 0900006485a20573 | |
| FDA-2007-D-0369-0862 | FDA | None FDA-2007-D-0369 | PSG_214012- Draft Guidance on Inclisiran Sodium | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:14Z | 1 | 0 | 0900006485a20575 | |
| FDA-2007-D-0369-0876 | FDA | None FDA-2007-D-0369 | PSG_207925 - Draft Guidance on Ivacaftor | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:14Z | 1 | 0 | 0900006485a2283a | |
| FDA-2007-D-0369-0872 | FDA | None FDA-2007-D-0369 | PSG_211911- Draft Guidance on Bimatoprost | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:22Z | 1 | 0 | 0900006485a22d9c | |
| FDA-2007-D-0369-0869 | FDA | None FDA-2007-D-0369 | PSG_215341- Draft Guidance on Finerenone | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:16Z | 1 | 0 | 0900006485a20d0d | |
| FDA-2007-D-0369-0864 | FDA | None FDA-2007-D-0369 | PSG_214460 - Draft Guidance on Brincidofovir | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:12Z | 1 | 0 | 0900006485a204e5 | |
| FDA-2007-D-0369-0870 | FDA | None FDA-2007-D-0369 | PSG_215383 - Draft Guidance on Belzutifan) | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:16Z | 1 | 0 | 0900006485a20d0f | |
| FDA-2007-D-0369-0873 | FDA | None FDA-2007-D-0369 | PSG_212194 -Draft Guidance on Givosiran Sodium | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:09Z | 1 | 0 | 0900006485a22802 | |
| FDA-2007-D-0369-0859 | FDA | None FDA-2007-D-0369 | PSG_213426 - Draft Guidance on Celecoxib; Tramadol Hydrochloride | Other | Guidance | 2023-05-19T04:00:00Z | 2023 | 5 | 2023-05-19T04:00:00Z | 2023-07-19T03:59:59Z | 2024-11-07T01:34:07Z | 1 | 0 | 0900006485a20571 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;